TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33811727

Group type: EXPERIMENTAL
Intervention: Gemcitabine 800 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study: 33812378

Group type: EXPERIMENTAL
Intervention: Age associations with lipid species
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Sex associations with lipid species
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Age-related associations by sex
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Age*sex interaction effects
Number of subjects: 980
Study: 33812381

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional HIV testing
Number of subjects: 17
Study: 33812665

Group type: EXPERIMENTAL
Intervention: Difficult tracheal intubation (defined as two failed attempts of direct laryngoscopy)
Number of subjects: 4683

Group type: EXPERIMENTAL
Intervention: Difficult tracheal intubation
Number of subjects: 4683
Study: 33812668

Group type: EXPERIMENTAL
Intervention: Anaesthesia for surgical or diagnostic procedures
Number of subjects: 5609
Study: 33812913

Group type: EXPERIMENTAL
Intervention: Radiation dose escalation with simultaneous integrated boost (SIB) technique, delivering 62.5-64 Gy/25-32 fractions to GTV, with SIB up to 70 Gy for pre-treatment 50% SUVmax area of GTV, plus 2 cycles of chemotherapy (cisplatin and fluorouracil) concurrently and 2 more cycles after radiotherapy.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Radiation dose escalation with SIB (Level 3&4)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Maximal dose of the esophagus (Dmax)
Number of subjects: 44
Study: 33813233

Group type: EXPERIMENTAL
Intervention: 2-item Insomnia Severity Index (ISI-2)
Number of subjects: 280
Study: 33813517

Group type: EXPERIMENTAL
Intervention: hCG/hMG
Number of subjects: 41

Group type: COMPARATOR
Intervention: GnRH pump
Number of subjects: 41
Study: 33813521

Group type: EXPERIMENTAL
Intervention: Intraoperative CM recordings from CI electrode contact during insertion with a 0.5 kHz tone burst stimulus.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postinsertion CM recordings from odd-numbered electrode contacts (1-15) using a range of stimulus frequencies (0.125 to 2 kHz).
Number of subjects: 14
Study: 33813550

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV administered without a loading dose at age-specific dose regimens 0.2-1.4 µg/kg/hr (< 6 yr) and 0.2-1.0 µg/kg/hr (≥ 6 yr)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV administered
Number of subjects: 61
Study: 33813580

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection
Number of subjects: 252

Group type: COMPARATOR
Intervention: Intravenous injection
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Knowledge of subcutaneous injection risk
Number of subjects: 252
Study: 33813631

Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 338

Group type: COMPARATOR
Intervention: Non-operative management
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Postoperative management
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Postoperative mortality
Number of subjects: 338
Study: 33813637

Group type: EXPERIMENTAL
Intervention: Antifungal therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Candida positive NHL
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Candida positive HL
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 90
Study: 33813673

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 772
Study: 33813727

Group type: EXPERIMENTAL
Intervention: Prasugrel 3.75 mg DAPT
Number of subjects: 203
Study: 33813736

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 25
Study: 33813771

Group type: EXPERIMENTAL
Intervention: Patients with recent onset of excessive daytime sleepiness (EDS), hypersomnia, or a suspected central disorder of hypersomnolence (CDH)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 500

Group type: COMPARATOR
Intervention: Patients with EDS due to severe sleep-disordered breathing, improving after therapy
Number of subjects: 500
Study: 33813842

Group type: EXPERIMENTAL
Intervention: Tailored treatment of nonphysiologic hemodynamic adjustments to pregnancy
Number of subjects: 0
Study: 33813864

Group type: EXPERIMENTAL
Intervention: More than 3 retrieval attempts
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Baseline Alberta Stroke Program Early CT Score of 8 to 9
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Baseline Alberta Stroke Program Early CT Score of 10
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Retrieval passes (median number 2, interquartile range 1–3)
Number of subjects: 593
Study: 33814177

Group type: EXPERIMENTAL
Intervention: Postoperative swallowing evaluation
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Risk factors for aspiration
Number of subjects: 182

Group type: COMPARATOR
Intervention: Comparison of aspirators vs nonaspirators
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Aspiration outcomes
Number of subjects: 182
Study: 33814284

Group type: EXPERIMENTAL
Intervention: PGD patients
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PGD patients who developed CLAD
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-PGD patients
Number of subjects: 99
Study: 33815252

Group type: EXPERIMENTAL
Intervention: Home group (H) - 7 outpatients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hospital group (URI) - 21 outpatients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups received 10 days of exergaming over 2 weeks, each session lasting a maximum of 1 hour.
Number of subjects: 28
Study: 33816283

Group type: EXPERIMENTAL
Intervention: Cs-131 implant after surgical resection
Number of subjects: 12
Study: 33816524

Group type: EXPERIMENTAL
Intervention: PT-Cy combined with tacrolimus and low-dose ATG
Number of subjects: 23
Study: 33817379

Group type: EXPERIMENTAL
Intervention: Topical diclofenac 25 mg/mL applied after laser microporation of cNF, reapplied twice daily for 3 days.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Physiological saline applied after laser microporation of cNF, reapplied twice daily for 3 days.
Number of subjects: 6
Study: 33817538

Group type: EXPERIMENTAL
Intervention: Preoperative insufficient endogenous analgesia
Number of subjects: 146

Group type: COMPARATOR
Intervention: Preoperative sufficient endogenous analgesia
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Preoperative sensory testing
Number of subjects: 146
Study: 33817543

Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the major risk alleles for low iron status
Number of subjects: 251

Group type: COMPARATOR
Intervention: Non-carriers of the major risk alleles for low iron status
Number of subjects: 251
Study: 33817650

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 66
Study: 33817648

Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted MRI (WB-DW MRI) after one treatment cycle of immunochemotherapy.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Interim assessment using Deauville criteria.
Number of subjects: 45

Group type: COMPARATOR
Intervention: End-of-treatment assessment using Deauville criteria.
Number of subjects: 45
Study: 33817686

Group type: EXPERIMENTAL
Intervention: MORPH intervention (mobile health behavior intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33817763

Group type: EXPERIMENTAL
Intervention: Working from home
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Each working hour at the computer
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Each work break taken
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Workstation ergonomics at home
Number of subjects: 69
Study: 33817960

Group type: EXPERIMENTAL
Intervention: High DAPT score (DS ≧2)
Number of subjects: 8383

Group type: COMPARATOR
Intervention: Low DAPT score (DS <2)
Number of subjects: 8383

Group type: EXPERIMENTAL
Intervention: Extended DAPT group (high DS)
Number of subjects: 8383

Group type: COMPARATOR
Intervention: Conventional DAPT group (low DS)
Number of subjects: 8383
Study: 33818006

Group type: EXPERIMENTAL
Intervention: Revascularization of PAD
Number of subjects: 30
Study: 33818022

Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (2.5 mg/daily) for 5 years
Number of subjects: 440
Study: 33818037

Group type: EXPERIMENTAL
Intervention: Monophasic response to OGTT
Number of subjects: 69
Study: 33818226

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants, alone or in combination with antiplatelet (AP)
Number of subjects: 2396
Study: 33818698

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) and left atrial (LA) myocardial deformation parameters (including global longitudinal strain (GLS), radial strain, circumferential strain, LA reservoir strain (LAε))
Number of subjects: 250
Study: 33819069

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33819614

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) treatment
Number of subjects: 42
Study: 33819776

Group type: EXPERIMENTAL
Intervention: OptiMEDs intervention
Number of subjects: 148
Study: 33820423

Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX LAA closure device
Number of subjects: 400
Study: 33820434

Group type: EXPERIMENTAL
Intervention: Methylation quantitative trait locus analysis
Number of subjects: 0
Study: 33820562

Group type: EXPERIMENTAL
Intervention: Deep learning model based on intraoperative monitoring data
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Deep learning model based on intraoperative intervention data
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Deep learning model based on combined preoperative, intraoperative intervention, and monitoring data
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Logistic regression model based on intraoperative monitoring data
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Random forest model based on intraoperative monitoring data
Number of subjects: 699
Study: 33820779

Group type: EXPERIMENTAL
Intervention: Sapanisertib plus exemestane (3 to 5 mg daily in phase IB, 25 mg daily)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sapanisertib plus fulvestrant (4 mg daily, 500 mg monthly)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 118
Study: 33820780

Group type: EXPERIMENTAL
Intervention: ABBV-085 monotherapy at 3.6 mg/kg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ABBV-085 plus gemcitabine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ABBV-085 at 3.6 mg/kg every 14 days
Number of subjects: 85
Study: 33820783

Group type: EXPERIMENTAL
Intervention: Pepinemab (10 mg/kg) with Avelumab (10 mg/kg), every 2 weeks
Number of subjects: 62
Study: 33820851

Group type: EXPERIMENTAL
Intervention: Secondary antibiotic prophylaxis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Definite rheumatic heart disease
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Borderline rheumatic heart disease
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall disease progression
Number of subjects: 53
Study: 33820958

Group type: EXPERIMENTAL
Intervention: Modified in vivo assay of hepatic propionate oxidative capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propionate oxidative capacity measurement
Number of subjects: 0
Study: 33822526

Group type: EXPERIMENTAL
Intervention: CAR-T cell therapy
Number of subjects: 0
Study: 33822795

Group type: EXPERIMENTAL
Intervention: Rural children with anemia
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Urban children with anemia
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Combined sample
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Households with more adults
Number of subjects: 1281
Study: 33822828

Group type: EXPERIMENTAL
Intervention: Pf-iRBC stimulation in Malian adults
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pf-iRBC stimulation in Malian children
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Macrophages re-exposed to Pf-iRBCs
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Monocytes of Malian adults
Number of subjects: 3
Study: 33822961

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33823018

Group type: EXPERIMENTAL
Intervention: PFS1 (complete mutism)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PFS2 (diminished speech)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PFS1
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PFS2
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: All children with PFS
Number of subjects: 178
Study: 33823051

Group type: EXPERIMENTAL
Intervention: Migraine-specific medications
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Acute medication use
Number of subjects: 170

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Migraine-specific medication use
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Older age and higher educational attainment
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Naturalistic assessment factors
Number of subjects: 170
Study: 33823783

Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention in addition to hepatitis C treatment
Number of subjects: 17
Study: 33823811

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SedLine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical assessments of anesthesia depth
Number of subjects: 100
Study: 33823862

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Control (non-prone position)
Number of subjects: 1057
Study: 33823929

Group type: EXPERIMENTAL
Intervention: High visceral adiposity
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Frozen tissue DDX11 expression
Number of subjects: 200
Study: 33824079

Group type: EXPERIMENTAL
Intervention: Endurance exercise (marathon running)
Number of subjects: 31
Study: 33824433

Group type: EXPERIMENTAL
Intervention: Intrabone (IB) infusion of umbilical cord blood transplantation (UCBT)
Number of subjects: 15
Study: 33824442

Group type: EXPERIMENTAL
Intervention: 10-day decitabine (20 mg/m2) combined with fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation (allo HCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard non-myeloablative (NMA) conditioning regimen
Number of subjects: 0
Study: 33824476

Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg daily)
Number of subjects: 66
Study: 33825230

Group type: COMPARATOR
Intervention: Add-on cannabidiol (two doses)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Add-on cinromide
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Add-on clobazam (three doses)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Add-on felbamate
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Add-on lamotrigine
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Add-on rufinamide
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Add-on topiramate
Number of subjects: 1277
Study: 33825489

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33825692

Group type: EXPERIMENTAL
Intervention: FibriCheck app
Number of subjects: 92
Study: 33825765

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AV-101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanicemine
Number of subjects: 0
Study: 33825916

Group type: EXPERIMENTAL
Intervention: Motion-compensated PET/CT
Number of subjects: 37

Group type: COMPARATOR
Intervention: 3D PET/CT
Number of subjects: 37
Study: 33825965

Group type: EXPERIMENTAL
Intervention: P2X3-Receptor Antagonist Gefapixant
Number of subjects: 253

Group type: COMPARATOR
Intervention: Prior medications (inhaled/oral steroids, antihistamines, antacids)
Number of subjects: 253
Study: 33826106

Group type: EXPERIMENTAL
Intervention: Ravulizumab (weight-based doses administered on days 1, 5, 10, and 15)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ravulizumab (modified dosing regimen)
Number of subjects: 22
Study: 33826112

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment (a complement C5 inhibitor)
Number of subjects: 51
Study: 33826209

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study: 33826362

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (replacing vincristine in the OEPA/COPDac regimen); two cycles of AEPA and four cycles of CAPDac; residual node radiotherapy (25.5 Gy) for non-CR sites after chemotherapy
Number of subjects: 77
Study: 33826508

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33826695

Group type: EXPERIMENTAL
Intervention: Yogurt consumption (per 25 g/d)
Number of subjects: 4365

Group type: EXPERIMENTAL
Intervention: High-fat milk consumption (per 100 g/d)
Number of subjects: 4365

Group type: EXPERIMENTAL
Intervention: Total nonfermented milk consumption (per 100 g/d)
Number of subjects: 4365

Group type: EXPERIMENTAL
Intervention: Hard cheese consumption
Number of subjects: 4365

Group type: EXPERIMENTAL
Intervention: Other dairy groups
Number of subjects: 4365
Study: 33826697

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) 900-1000 kcal/d for 28 days
Number of subjects: 37
Study: 33826820

Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 24
Study: 33826860

Group type: EXPERIMENTAL
Intervention: Structured Advance Care Planning Elements in the Electronic Health Record
Number of subjects: 0
Study: 33827114

Group type: EXPERIMENTAL
Intervention: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg) for 8 cycles followed by transplant and 1 year of lenalidomide maintenance (10 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg)
Number of subjects: 46
Study: 33827116

Group type: EXPERIMENTAL
Intervention: KTE-X19 at 1 × 10^6 cells per kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: KTE-X19 in all patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: KTE-X19 with revised AE management at 1 × 10^6 cells per kg
Number of subjects: 54
Study: 33827139

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) combined with nivolumab (Nivo)
Number of subjects: 91
Study: 33827446

Group type: EXPERIMENTAL
Intervention: Caregiver Activity Scale (CAS)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Zarit Burden Interview (ZBI)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Awareness of dementia diagnosis (caregivers)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Awareness of dementia diagnosis (patients)
Number of subjects: 524
Study: 33827501

Group type: EXPERIMENTAL
Intervention: Enhanced after-school programming with structured nutrition education and minimum physical activity requirements
Number of subjects: 76
Study: 33827611

Group type: EXPERIMENTAL
Intervention: Overnight sleep registration for OSA diagnosis
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire
Number of subjects: 49
Study: 33827675

Group type: EXPERIMENTAL
Intervention: Glucose metabolism in the right middle temporal gyrus (RMTG)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: RMTG metabolism
Number of subjects: 149
Study: 33827827

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy activities during the interventional period
Number of subjects: 69
Study: 33827861

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR) eyes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR) eyes with proliferative DR
Number of subjects: 62
Study: 33827960

Group type: EXPERIMENTAL
Intervention: Baseline plasma neurofilament light chain (NfL) concentrations measured with single-molecule array
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Plasma NfL
Number of subjects: 574
Study: 33828254

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily plus Pembrolizumab 200 mg every 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 33828507

Group type: EXPERIMENTAL
Intervention: Computer-aided imagery training (CAIT)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Healthy control subject
Number of subjects: 1
Study: 33828518

Group type: EXPERIMENTAL
Intervention: Zika virus infection
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Acute Illness of Unidentified Origin (AIUO)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Dengue virus infection
Number of subjects: 406
Study: 33828613

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 33829021

Group type: EXPERIMENTAL
Intervention: Monitoring serum NET levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modulating the balance between NET formation and removal
Number of subjects: 0
Study: 33829030

Group type: EXPERIMENTAL
Intervention: Enhanced High-Volume Preparation for Colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Low-Volume Preparation for Colonoscopy
Number of subjects: 0
Study: 33829034

Group type: EXPERIMENTAL
Intervention: Higher Protein/Low Glycemic Index Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Diet
Number of subjects: 0
Study: 33829237

Group type: EXPERIMENTAL
Intervention: Fruit juice intake at 1 year old (120 mL per day)
Number of subjects: 783
Study: 33829305

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) procedure comprising 3 cycles of brachial cuff inflation to 200 mmHg for 5 min followed by deflation to 0 mmHg for another 5 min, performed at study inclusion and repeated after 12 and 24 hours.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) procedure repeated after 12 and 24 hours.
Number of subjects: 26
Study: 33829355

Group type: EXPERIMENTAL
Intervention: CKD-516 in combination with intravenous irinotecan (120 mg/m2), administered for five consecutive days followed by two days off.
Number of subjects: 0